Avience Biomedicals Limited Link 
Allotment
Avience Biomedicals Limited is a healthcare diagnostics company with over 20 years of experience in molecular biotechnology and in-vitro diagnostics. The company is engaged in the manufacturing and supply of diagnostic kits, molecular testing products, and healthcare solutions, serving hospitals, laboratories, and healthcare providers across India through its research-driven and quality-focused operations.Avience Biomedicals IPO will open for subscription on June 18, 2026, and close on June 22, 2026. The company plans to raise approximately ₹30.24 crore through a fresh issue at a price band of ₹196 to ₹208 per share. The IPO is scheduled to list on NSE on June 25, 2026, with the allotment expected on June 23, 2026.
₹208
0%
Open
₹208
HIgh - Low
₹208
Previous Close
₹208
Total Traded Value
0
52 Weeks High
₹208
52 Weeks Low
₹208
Updates On
Jun 5, 2026
IPO. Open
Jun 18, 2026
IPO. Close
Jun 22, 2026
IPO. Price
₹208.00
IPO Market price
₹114.09 Cr
IPO Details
| IPO Date | 25 Jun |
| IPO Listing Date | 25 Jun |
| IPO Face Value | ₹10 Per Equity Share |
| IPO Price Range | ₹208.00 |
| IPO Issue Size | Approx ₹30.24 Crores |
| IPO Sale Type | Fresh capital cum OFS |
| Employee Discount | |
| IPO Issue Type | Book build Issue |
| IPO Listing | NSE SME Platform |
| hare Holding Pre Issue | 40,31,256 shares |
IPO Timeline
| IPO Open Date | 18 Jun |
| IPO Close Date | 22 Jun |
| IPO Allotment (Tentative) | 23 Jun |
| Refunds | 24 Jun |
| Credit to Demat Account | 24 Jun |
| IPO Listing Date | 25 Jun |
IPO Reservation
| Category | Offer |
|---|---|
| QIB Shares Offered | 2,73,600 Shares |
| NII (HNI) Shares Offered | 2,07,000 Shares |
| Retail Shares Offered | 4,81,200 Shares |
IPO Lot Size
–
| Application | Lots | Share | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 1,200 | ₹2,49,600 |
| Retail (Max) | 2 | 1,200 | ₹2,49,600 |
| S-HNI (Min) | 3 | 1,800 | ₹3,74,400 |
| S-HNI (Max) | 8 | 4,800 | ₹9,98,400 |
| B-HNI (Min) | 9 | 5,400 | ₹11,23,200 |
Avience Biomedicals Limited is a healthcare and diagnostics company with over 20 years of experience in molecular biotechnology, genomics, molecular markers, and in-vitro diagnostics (IVD). The company develops, manufactures, supplies, and distributes diagnostic products and healthcare solutions, focusing on innovative and affordable diagnostics for both urban and rural populations. It also partners with international healthcare technology companies to bring advanced diagnostic solutions to the Indian market.
Product Portfolio
Dengue Diagnostic Kits
Dengue NS1 Antigen Test Kits
Malaria Rapid Test Kits (Pan/Pf)
Malaria Rapid Test Kits (Pf/Pv)
Typhoid IgG/IgM Antibody Test Kits
Pregnancy Test Strips
Pregnancy Test Cards
COVID-19 Detection Kits
COVID-19 RT-qPCR Assay Kits
Syphilis Rapid Test Kits
Viral Transport Medium (VTM)
Molecular Diagnostic Products
In-Vitro Diagnostic (IVD) Products
Genomics and Molecular Biotechnology Solutions
The company is engaged in the development and manufacturing of diagnostic kits and molecular diagnostic products while maintaining a strong distribution network across India. Supported by an in-house research team, Avience continuously works on identifying new molecular markers and developing innovative diagnostic solutions for disease detection, risk assessment, and healthcare applications. It serves over 500 clients and has a presence across 120+ cities in India.
Company Financials (Consolidated)
| Assets | 66.07 | 56.52 | 34.65 |
| Total Income | 41.94 | 45.97 | 24.37 |
| Profit After Tax | 5.74 | 7.23 | 2.14 |
| EBITDA | 10.34 | 11.41 | 4.08 |
| NET Worth | 28.52 | 22.78 | 6.21 |
| Reserves and Surplus | 24.49 | 18.75 | 2.93 |
| Total Borrowing | 26.73 | 22.16 | 15.13 |
Key Performance Indicator (KPI)
| ROE | 22.38% |
| ROCE | 24.88% |
| Debt/Equity | 0.97 |
| RoNW | 49.89% |
| PAT Margin | 15.86% |
| EBITDA Margin | 25.22% |
| Price to Book Value | - |
IPO Objects of the Issue
| S.No. | Objects of the ipo Resources Detail | IPO Amount |
|---|---|---|
| 1 | Funding capital expenditure requirements for the purchase of equipment/machineries | - |
| 2 | To meet out the expenses of Working Capital Requirement | ₹8.25 |
| 3 | To meet out the General Corporate Purposes; | - |
| 4 | Offer for Sale (OFS) | - |
Contact Details
Avience Biomedicals Ltd.
C-11, Block-C
Community Centre,
Janakpuri A-3,
Delhi, New Delhi, 110058
Phone: 1800-12-04-636
Email: info@avienbio.com
Website: https://avienbio.com/
Detail Registrar
Skyline Financial Services Pvt. Ltd.
Phone: 02228511022
Email: ipo@skylinerta.com
Website: https://www.skylinerta.com/ipo.php
The IPO of Avience Biomedicals Limited is a SME book-built issue to raise approximately ₹30.24 crore through a fresh issue and offer for sale. The price band is ₹196 to ₹208 per share.
The IPO will open on 18 June 2026 and close on 22 June 2026 for public subscription.
The IPO is expected to be listed on 25 June 2026 on the NSE SME platform after allotment and refund processing.
The price band is fixed between ₹196 and ₹208 per share. The minimum retail application is 1,200 shares, requiring an investment of around ₹2.49 lakh.
Avience Biomedicals Limited is engaged in manufacturing and supplying diagnostic kits, molecular testing products, and in-vitro diagnostic (IVD) solutions for hospitals and laboratories.
The company plans to utilize IPO proceeds for setting up a new manufacturing unit, meeting working capital requirements, and general corporate purposes.
It will list on the BSE SME platform.
The company has reported strong profitability with around 15.86% PAT margin, ROE of about 22%, and ROCE of nearly 24%, indicating stable financial performance.
The issue allocation includes Retail (33.10%), QIB (18.82%), NII (14.24%), and Anchor investors (28.19%) portions.
The company offers a wide range of diagnostic products including dengue, malaria, typhoid, COVID-19, pregnancy test kits, and other molecular diagnostic solutions used across healthcare facilities.
Compare:
